Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Men's Hormone Health

CoverageMen's Hormone Health

Do aromatase inhibitors in men increase bone loss risk?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·14 studies analyzed·2 core studies·Applies to: hypogonadal men

Bottom line

Aromatase inhibitors lower estradiol and can reduce bone mineral density in men. Routine use to suppress estradiol during testosterone therapy is not supported by outcome evidence and may carry skeletal risk.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Long-term fracture and bone-density outcome data in men routinely treated with aromatase inhibitors during TRT are limited.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Anastrozole men osteoporosis▼

Aromatase inhibitors lower estradiol and can reduce bone mineral density in men. Routine AI use to suppress estradiol during TRT is not supported by fracture outcomes.

Do aromatase inhibitors cause bone loss in men on TRT?▼

Yes — estradiol is essential for male bone health. Aromatase inhibitors that suppress estradiol below normal physiologic ranges risk reduced bone mineral density without established fracture outcome data.

Estradiol and bone density in men▼

In men, low estradiol is a stronger predictor of low bone density and fracture risk than low testosterone alone. Monitoring estradiol during AI use in men is appropriate.

Should men on TRT take anastrozole for bone protection?▼

Evidence does not support routine anastrozole use in men on TRT for bone protection. Managing TRT dose and formulation to maintain estradiol in physiologic range is a safer approach.

AI use in male TRT▼

Aromatase inhibitors lower estradiol and can reduce bone mineral density in men. Routine use to suppress estradiol during testosterone therapy is not supported by outcome evidence and may carry skeletal risk.

Do aromatase inhibitors cause bone loss in men?▼

Aromatase inhibitors lower estradiol and can reduce bone mineral density in men. Routine use to suppress estradiol during testosterone therapy is not supported by outcome evidence and may carry skeletal risk.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 12 relevant studies.

Overall finding

3 studies address bone mineral density, with weighted findings showing no meaningful effect. 2 studies address sleep-related cognitive symptoms, with weighted findings showing a positive association. 2 studies address venous thromboembolism, with weighted findings showing no meaningful effect. 1 study addresses fractures, with weighted findings showing no meaningful effect. 5 randomized or systematic-review reports and 6 observational studies address treatment. Reserve aromatase inhibitors for selected clinical scenarios rather than routine estradiol suppression during testosterone therapy.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Reassuring

Bone mineral density

high · 3 studies

3 studies address bone mineral density, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 26901812PMID 19820017PMID 11730247
Positive link

Sleep-related cognitive symptoms

high · 2 studies

2 studies address sleep-related cognitive symptoms, with weighted findings showing a positive association.

Mixed measurement

Studies

PMID 34536053PMID 35904664
Reassuring

Venous thromboembolism

moderate · 2 studies

2 studies address venous thromboembolism, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 37326322PMID 26205547
Reassuring

Fractures

moderate · 1 study

1 study addresses fractures, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 19820017
Unclear

Weight / body composition

moderate · 1 study

1 study addresses weight / body composition, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 35904664
Unclear

Quality of life

moderate · 1 study

1 study addresses quality of life, with weighted findings showing unclear findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 35904664

Magnitude / clinical importance

Validated effect estimates in the analyzed set include or 10. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Most studies agree on quality of life (unclear findings), while bone mineral density findings are no meaningful effect and more consistent across domains.

Supports main conclusion: 1 · Neutral / mixed: 11 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • Estrogens primarily regulate bone homeostasis in adult men, and testosterone and estradiol levels must decline substantially to impact the skeleton.
  • It has generally been held that estrogen and testosterone are the major sex steroids regulating bone metabolism in women and men, respectively.
  • The results indicated that OSA is significantly correlated with the decrease in serum testosterone levels in men.
  • In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac e…

Risks & harms

4 studies report safety-relevant findings. Design mix: Randomized controlled trial, Study design not clearly classified, Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included hypogonadal men.

What remains uncertain

  • Long-term fracture and bone-density outcome data in men routinely treated with aromatase inhibitors during TRT are limited.
  • Long-term fracture and bone-density outcome data in men routinely treated with aromatase inhibitors during TRT are limited.

Clinical takeaway

Monitor bone density when estradiol is intentionally lowered, and reconsider the risk-benefit balance if skeletal markers decline.

Reassuring

Bone mineral density?

No meaningful effect

high[26901812 · 19820017 · 11730247]

Positive link

Sleep-related cognitive symptoms?

A positive association

high[34536053 · 35904664]

Reassuring

Venous thromboembolism?

No meaningful effect

moderate[37326322 · 26205547]

Reassuring

Fractures?

No meaningful effect

moderate[19820017]

Unclear

Weight / body composition?

Unclear findings

moderate[35904664]

Unclear

Quality of life?

Unclear findings

moderate[35904664]

Unclear

Fertility / spermatogenesis?

Unclear findings

limited[27855957]

5 randomized or systematic-review reports and 6 observational studies address treatment. Weighted treatment findings show mixed findings.

5 RCT / systematic review · 6 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

12 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

13 analyzed studies

Strongest evidence

Supporting literature

Association between obstructive sleep apnea and male serum testosterone: A systematic review and meta-analysis.

Obstructive sleep apnea and serum total testosterone: a system review and meta-analysis.

Cardiovascular Safety of Testosterone-Replacement Therapy.

+9 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Men's Hormone Health.

Does testosterone replacement increase cardiovascular risk?

Large randomized data (including TRAVERSE) do not show a significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men over median follow-up of roughly three years. Older observational studies conflict, and absolute risk depends on baseline cardiovascular disease, formulation, and monitoring.

11 linked studies

Does testosterone therapy increase prostate cancer risk?

Current systematic reviews and trial secondary analyses do not show a convincing increase in prostate cancer incidence among hypogonadal men treated with testosterone, though surveillance remains standard practice.

14 linked studies

Does testosterone therapy increase hematocrit and polycythemia risk?

Testosterone therapy commonly raises hematocrit; polycythemia is a recognized adverse effect requiring dose adjustment, formulation changes, or phlebotomy when thresholds are exceeded.

14 linked studies

Does testosterone therapy suppress fertility in men?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reliably reduces spermatogenesis. Recovery after discontinuation is variable and may be incomplete in some men.

14 linked studies

Go deeper on Men's Hormone Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Men's Hormone HealthView pricing